Article Sidebar

pdf
Date Published: 25/09/2023
Abstract Views: 307
Views pdf: 197
DOI: https://doi.org/10.51298/vmj.v530i1B.6664
Issue
Vol. 530 No. 1B (2023)
Section
Các bài báo
How to Cite
Thân, V. T., & Bùi, V. Q. (2023). THE RESULTS OF PACLITAXEL REGIMEN FOR RECURRENT OR METASTATIC IN BREAST CANCER. Vietnam Medical Journal, 530(1B). https://doi.org/10.51298/vmj.v530i1B.6664

THE RESULTS OF PACLITAXEL REGIMEN FOR RECURRENT OR METASTATIC IN BREAST CANCER

Văn Thịnh Thân1,, Vinh Quang Bùi1
1 Hanoi Oncology Hospital

Main Article Content

Abstract

Objectives: Describe some clinical and subclinical characteristics of metastatic breast cancer patiens and evaluate the results of paclitaxel regimen for recurrent or metastatic in breast cancer. Patients and methods: A retrospective study on 120 patients with recurrent or metastatic in breast cancer were treated with paclitaxel chemotherapy regimen at Hanoi Oncology Hospital from 01/2018 to 01/2022. Results: 120 patients enrolled, the average age was 59.6 ± 8.8. The overall response rate (ORR) of the regimen was 37.5 %. The mean progression-free survival was 8.6±2.34 months. The rate overall survival 3 years was 35.5%. The rate overall survival 5 years was 20,0%. The common toxicity was hair loss (37,5%), anorexia (25.0%), nausea (6.7%), diarrhea (5.8%); allergy (1.6%). Conclusion: Treatment of metastatic recurrent breast cancer with Paclitaxel regimen has a relatively good response rate, which improves progression-free survival and overall survival for patients.

Article Details

Keywords

Paclitaxel, metastatic breast cancer, progression-free survival, overall survival.

References

Bray F., Ferlay J., Soerjomataram I., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6), 394–424.
2. Nguyễn Bá Đức, Nguyễn Chấn Hùng và cs. (2017). Kết quả bước đầu nghiên cứu đánh giá hiệu quả phác đồ AC-T trên bệnh nhân ung thư vú ở bệnh viện K giai đoạn 2015-2016. Tạp chí Y học thực hành, 489, tr 10-17.
3. Jame F.Bishop., Joanna Dewar., Guy C. Toner and et al (1999). Intial Paclitaxel improves out come compared with CMFP combination chemotherapy as front line therapy in untreated mestastatic Breast cancer. J Clin Oncol, 17(8), 2355 – 2364.
4. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics. CA cancer J.Clin. 2014, 64: 9-29.
5. Tạ Văn Tờ (2004). Nghiên cứu hình thái học, hóa mô miễn dịch và giá trị tiên lượng của chúng trong ung thư biểu mô tuyến vú. Luận án Tiến sỹ Y học. 34-6
6. Bishop J.F., Dewar J., Toner G.C. và cộng sự. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol, 17(8), 2355–2364.
7. Sledge G.W., Neuberg D., Bernardo P. và cộng sự. (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol Off J Am Soc Clin Oncol, 21(4), 588–592.
8. Phạm Thị Dịu, Lê Thanh Đức (2022). Đánh giá kết quả hóa trị phác đồ paclitaxel trong ung thư vú tái phát di căn. 517(1), 308-312